Default company panoramic image

AAVP Biosystems, Inc.

AAVP has discovered a novel way to deliver treatment to cancer cells while avoiding healthy cells & has validated its technology.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Houston, TX, USA
  • Currency USD
  • Founded January 2012
  • Employees 3

Company Summary

AAVP Biosystems has developed a targeted therapy for the treatment of cancer. Cancer treatment requires a careful balance between maximizing therapeutic efficacy & minimizing toxicity. The ideal therapy would specifically & selectively target tumor cells while “ignoring” normal healthy cells. AAVP has developed a targeted gene delivery vector that that meets this goal and positions AAVP as a leader in personalized medicine.


  • D3265d24 78a0 4749 afcc 02de656131f1
    President & CEO

    C. Richard Piazza has over 35 years of significant international healthcare experience in medical devices, pharmaceuticals/biotech and healthcare services in companies ranging in size from large multi-nationals to raw startups. As a CEO for 28 years, he has led both public (AMEX, NASDAQ & TSX) and private companies to enviable records of financial and clinical success and has raised more than $150 million in both private and public equity.

  • Default avatar
    Steven K. Libutti, MD
    Director, Founder & CSO

    Dr. Libutti is the Director of the Montefiore-Einstein Center for Cancer Care, Professor and Vice-Chairman, Department of Surgery and Professor in the Department of Genetics at the Albert Einstein College of Medicine & the Montefiore Medical Center. Formerly a Senior Investigator & Chief of the Tumor Angiogenesis Section in the Surgery Branch, NCI his lab focused on studies of the pathogenesis of neuroendocrine tumors & on the familial cancer

  • Default avatar
    Renata Pasqualini, PhD

    Dr. Pasqualini has published over 150 scientific studies and holds or has applied for more than 100 patents worldwide.

    Dr. Pasqualini and Dr. Arap are scientific founders of five new biotechnology start-up companies, including AAVP Biosystems, Ablaris Therapeutics, Alvos Therapeutics, AMP Pharm., and Ceramide Therapeutics. Ablaris and Alvos are publicly traded as part of the portfolio of Arrowhead Research Corporation (NASDAC ARWR).

  • 9163f770 67ac 4f04 8358 d9bf851431b1

    Wadih Arap, MD, PhD is the new Deputy Director of the UNM Cancer Center and Chief of the Division of Hematology/Oncology in the Department of Internal Medicine in the School of Medicine. Formerly, Stringer Professor of Medicine & Experimental Diagnostic Imaging and Deputy Chair of the Department of Genitourinary Medical Oncology in the Division of Cancer Medicine at MD Anderson Cancer Center he has over 60 patents & 150 scientific studies

Previous Investors

  • Default avatar